clinical trial · NCT02016924
Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV
Gilead Sciences·phase3·active not recruiting·n = 133
Acquired Immune Deficiency Syndrome (AIDS)HIV InfectionsATVDRVCobicistatBRF/TAFLPV/rThird Unboosted DrugCobicistat TOS
brief summary
The goal of this clinical study is to learn more about the safety and dosing of study drugs, cobicistat-boosted Atazanavir (ATV/co), cobicistat-boosted darunavir (DRV/co) and emtricitabine/tenofovir alafenamide (F/TAF), in children (age ≥ 4 weeks to \< 18 years) with HIV.
started
Jan 16, 2014
primary completion
Jun 13, 2025
completion
Mar 1, 2027
last updated
Apr 21, 2026
official title
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol